MedPath

Follow-up of Abnormal and Inadequate Smear-test Results

Not Applicable
Conditions
Carcinoma in Situ of Uterine Cervix
Interventions
Other: Test result sent by letter
Other: Test result conveyed by general practitioners
Registration Number
NCT02002468
Lead Sponsor
University of Aarhus
Brief Summary

Denmark has a higher incidence of cervical cancer than other Nordic countries, although all Danish women (aged 23-65) are screened regularly to identify possible cervical dysplasia or asymptomatic invasive cancer.

Annually 40 000 women receives an abnormal or inadequate test result and a follow-up recommendation.

However problems with delayed follow-up may threaten the effectiveness of the Danish Cervical Cancer Screening Program, as 20% of women are delayed and dysplasia potentially can progress into cancer.

Delayed follow-up is found in situations where women either consciously or unconsciously postpone follow-up, or because of organizational aspects of the screening program, where communication regarding test results can fail either in content or with delay.This study will evaluate two interventions designed to increase follow-up:

1. A letter with the test result and potential recommendation for follow up will be sent to the women (RCT). The intention is to ensure that all women will be notified about the test result, quickly, homogenously and in layman's written language, still with the opportunity to contact or be contacted by the general practitioner, if there is special needs. Furthermore, it is assumed that general practitioner consultations regarding delivery of normal test results will decrease, so that cost savings is a potential side benefit

2. Electronic reminder to the general practitioner if women have not had the recommended follow up, giving the general practioner´s an opportunity to remind the women (retro perspective cohort study).

The results will be of great importance to the future organisation of cervical and colorectal cancer screening programmes in Denmark, but will also have international interest because of their similar challenges.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
125000
Inclusion Criteria
  • woman with a pap-smear test
Read More
Exclusion Criteria
  • less than 23 years
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Test result sent by letterTest result sent by letterThe pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
Test result sent by letterTest result conveyed by general practitionersThe pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
Test result conveyed by general practitionersTest result conveyed by general practitionersIn Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
Primary Outcome Measures
NameTimeMethod
Proportion of women with timely follow-up1½ year

The proportion of women followed up will be calculated as cumulated incidence proportions according to four timeframes (undesirable early, as recommended, late, very late), and be compared by relative risks. The results will be presented in totals and separately depending on the test result (normal/inadequate/Bethesda classification 2001/HPV).

Secondary Outcome Measures
NameTimeMethod
Frequency of general practitioner contacts (consultations/telephone calls /e-mails) regarding conveying the smear test result.Three months after the smear test.

The two randomisation groups will be compared with respect to contacts with general practitioner after the smear test the first days, weeks, months after the general practitioner is notified of the screening result.

Trial Locations

Locations (1)

University of Aarhus

🇩🇰

Aarhus, Central Denmark Region, Denmark

© Copyright 2025. All Rights Reserved by MedPath